KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax: 2011-2024

Historic Long-Term Deferred Tax for Regeneron Pharmaceuticals (REGN) over the last 14 years, with Dec 2024 value amounting to $3.3 billion.

  • Regeneron Pharmaceuticals' Long-Term Deferred Tax rose 27.58% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 27.58%. This contributed to the annual value of $3.3 billion for FY2024, which is 28.68% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $3.3 billion for FY2024, which was up 28.68% from $2.6 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $3.3 billion during FY2024, with a 5-year trough of $858.9 million in FY2020.
  • Its 3-year average for Long-Term Deferred Tax is $2.5 billion, with a median of $2.6 billion in 2023.
  • Data for Regeneron Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY surged of 96.57% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Long-Term Deferred Tax stood at $858.9 million in 2020, then rose by 2.10% to $876.9 million in 2021, then soared by 96.57% to $1.7 billion in 2022, then soared by 49.41% to $2.6 billion in 2023, then rose by 28.68% to $3.3 billion in 2024.